Welcome to our dedicated page for Inmed Pharmaceuticals news (Ticker: INM), a resource for investors and traders seeking the latest updates and insights on Inmed Pharmaceuticals stock.
InMed Pharmaceuticals Inc. (NASDAQ: INM) is a pharmaceutical drug development company that regularly issues news and updates about its proprietary small molecule programs and related corporate activities. The company focuses on drug candidates targeting the CB1/CB2 receptors in three main therapeutic areas: Alzheimer’s disease, ocular conditions and dermatological indications, and it also reports on the commercial operations of its rare cannabinoid subsidiary BayMedica.
News about InMed often covers progress in its lead Alzheimer’s program INM-901, including preclinical data, pharmacokinetic studies in animal models and scientific presentations at major conferences such as the Alzheimer’s Association International Conference (AAIC). Releases describe how INM-901 is being evaluated across multiple biological pathways associated with Alzheimer’s disease and summarize findings from long-term studies in established disease models.
Investors and followers of INM can also find updates on INM-089, a proprietary small molecule drug candidate under investigation for dry age-related macular degeneration, including preclinical study results and formulation work for intravitreal delivery. In addition, InMed provides business updates on BayMedica, including sales performance, legislative developments affecting rare, non-intoxicating cannabinoids and the subsidiary’s evaluation of alternative supply chain options to maintain regulatory compliance.
Corporate and capital markets developments are another frequent theme in InMed’s news flow. The company announces private placements, preferred investment option amendments, participation in investor conferences, and changes to its board of directors, as well as the outcomes of its annual general and special meetings of shareholders. For readers tracking INM news, this page offers a centralized view of scientific, commercial, financial and governance announcements directly tied to the company’s disclosed activities.
InMed Pharmaceuticals (Nasdaq: INM) announced key developments in its Phase 2 clinical trial for INM-755 cannabinol cream targeting epidermolysis bullosa (EB). The trial has expanded to include adolescents aged 12-17 after safety data review, with the first adolescent patient successfully enrolled and treated. Additionally, a patent for CBN's use in EB treatment has been granted in Japan, enhancing InMed's intellectual property portfolio. Currently, eight clinical trial sites across Europe are activated, with two more expected soon, aiming for 20 enrolled patients by the end of 2022.
InMed Pharmaceuticals Inc. (Nasdaq: INM) has appointed Michael Woudenberg as the new Chief Operating Officer, effective immediately. Woudenberg, who previously served as Senior Vice President of Chemistry, Manufacturing and Controls, has significant experience in drug development and manufacturing. His promotion is expected to strengthen operational leadership as InMed pursues its strategic growth in rare cannabinoid therapeutics. Eric A. Adams, the company's President and CEO, endorsed the decision, highlighting Woudenberg's integral role within the organization over the past four years.
InMed Pharmaceuticals (Nasdaq: INM) has received a notice from Nasdaq indicating that its stock has been trading below the $1.00 minimum bid price for 30 consecutive days. The Company has 180 days to regain compliance and will continue to trade during this period. If compliance is not met, InMed may face delisting, although it can appeal the decision. The Company plans to monitor its stock price closely and explore options to comply with Nasdaq listing requirements.
InMed Pharmaceuticals Inc. (Nasdaq: INM) announced a peer-reviewed study published in the International Journal of Molecular Sciences, highlighting rare cannabinoids' effects on skin conditions. Conducted by Dr. Mauro Maccarrone and his team, the study focused on tetrahydrocannabivarin (THCV), cannabichromene (CBC), and others. Results indicate varying biological activities, with THCV acting as a cannabinoid receptor 1 antagonist. This research supports further exploration into rare cannabinoids for therapeutic applications in skin diseases, aligning with InMed's commitment to advancing cannabinoid science.
InMed Pharmaceuticals has officially launched B2B sales of the rare cannabinoid d9-THCV through its subsidiary BayMedica, targeting the health and wellness sector. Rigorous testing and GMP standards ensure high product quality. Research highlights d9-THCV's potential benefits, including appetite suppression and blood sugar regulation. The cannabinoid market is projected to grow to US$26 billion by 2028 with a CAGR exceeding 20%. InMed aims to solidify its position as a leading supplier in this emerging market.
InMed Pharmaceuticals (Nasdaq: INM) has successfully closed a registered direct offering and a concurrent private placement, raising approximately $5 million. The offerings involved issuing 4,079,256 common shares and 1,748,250 shares at a price of $0.858 each to a healthcare-focused institutional investor. Additionally, InMed issued investment options for purchasing up to 5,827,506 common shares. Proceeds will be used for pipeline development, commercial activities, and general working capital needs. The unregistered options have an exercise price of $0.74, expirating in six and a half years.
InMed Pharmaceuticals has announced a securities purchase agreement with a healthcare-focused institutional investor for the issuance of 4,079,256 common shares at $0.858 each, resulting in gross proceeds of approximately $5 million. This offering includes a concurrent private placement for an additional 1,748,250 shares at the same price. The company plans to utilize the net proceeds for pipeline development and commercial activities. Additionally, existing warrants will be amended to reduce their exercise price to $0.74 per share, enhancing the facility for investors.
InMed Pharmaceuticals Inc. (Nasdaq: INM) reported its Q3 fiscal 2022 results, highlighting advancements in its rare cannabinoid products, including the launches of CBDV and CBT. The company saw a net loss of $10.7 million, or $0.81 per share, compared to a loss of $6.9 million, or $1.11 per share, for the same period last year. InMed's BayMedica segment generated $0.6 million in net sales. The company is also advancing clinical trials for its therapeutic candidates, including INM-755 for Epidermolysis Bullosa and INM-088 for glaucoma. Cash and short-term investments stood at $5.9 million as of March 31, 2022.
InMed Pharmaceuticals (Nasdaq: INM) announced that its subsidiary, BayMedica, will supply rare cannabinoids for Radicle Science's study on the effects of delta-9 dominant tetrahydrocannabivarin (THCV) on health outcomes like energy, focus, appetite, and weight/BMI. This consumer-based research will involve up to 900 participants in a randomized, placebo-controlled trial, beginning participant recruitment in May 2022 and expected to last four weeks. Results will inform consumers and healthcare providers on the efficacy of THCV as part of broader cannabinoid research.
InMed Pharmaceuticals (INM) is transitioning from a pure-play pharmaceutical R&D firm to include commercial sales in the health and wellness market. Upcoming product launches of high-value rare cannabinoids are expected to drive revenue growth. The company is also advancing its pharmaceutical drug programs, including a Phase II trial and preparations for an FDA meeting for its glaucoma drug candidate INM-088. Valuation scenarios have been updated, reflecting a risk-adjusted per basic share value ranging from US$1.5 to US$16.0.